In short
This article explores the ongoing clinical trials investigating the use of Elebsiran (VIR-2218) for treating chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Elebsiran is being studied alone and in combination with other therapies to assess its safety, efficacy, and potential to achieve functional cure in patients with these chronic viral liver infections.
At a glance
- Drug Name
- Elebsiran (VIR-2218)
- Conditions Studied
- Chronic Hepatitis B Virus (HBV) Infection, Chronic Hepatitis D Virus (HDV) Infection
- Administration
- Subcutaneous injection
- Dosing
- Maximum daily dose: 200 mg; Maximum total dose: 2600-9600 mg
- Treatment Duration
- 48-214 weeks, depending on the trial
- Primary Objectives
- Evaluate efficacy, safety, and tolerability
- Key Endpoints
- HBsAg loss, HBV DNA suppression, ALT normalization, functional cure
- Study Phases
- Phase 2
- Combination Therapies
- Studied alone and in combination with other agents (e.g., VIR-3434, peginterferon alfa-2a)
- Patient Population
- Adults with chronic HBV or HDV infection, meeting specific eligibility criteria
What is ELEBSIRAN?
ELEBSIRAN, also known as VIR-2218, is an investigational drug being developed to treat chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. It belongs to a class of drugs called small interfering RNA (siRNA), which are designed to silence specific genes.
Medical Conditions Treated
ELEBSIRAN is being studied for the treatment of:
- Chronic Hepatitis B Virus (HBV) Infection: A long-term liver infection that can lead to serious health problems if left untreated.
- Chronic Hepatitis D Virus (HDV) Infection: A severe form of viral hepatitis that occurs only in people who are already infected with HBV.
How ELEBSIRAN Works
ELEBSIRAN is designed to work by:
- Targeting viral genes: It specifically targets genes essential for HBV and HDV replication.
- Reducing viral proteins: By silencing these genes, ELEBSIRAN aims to reduce the production of viral proteins, including hepatitis B surface antigen (HBsAg).
- Suppressing viral replication: The overall goal is to suppress the replication of HBV and HDV in infected liver cells.
Administration
ELEBSIRAN is administered as a subcutaneous injection, which means it is injected under the skin. The dosing schedule and duration of treatment may vary depending on the specific clinical trial protocol.
Clinical Trials
ELEBSIRAN is currently being evaluated in several clinical trials:
- SOLSTICE Study: A Phase 2 trial evaluating ELEBSIRAN in combination with another investigational drug (VIR-3434) for chronic HDV infection.
- PREVAIL Study: A Phase 2 platform study assessing ELEBSIRAN along with other investigational therapies for chronic HBV infection.
- VIR-2218-1006 Study: Another Phase 2 trial examining ELEBSIRAN in combination with VIR-3434 and/or pegylated interferon alfa-2a for chronic HBV infection.
Efficacy
The clinical trials are designed to evaluate ELEBSIRAN's efficacy through various measures, including:
- Viral suppression: Reduction in HBV DNA and HDV RNA levels.
- HBsAg loss: Proportion of patients achieving undetectable levels of hepatitis B surface antigen.
- Functional cure: Defined as undetectable HBsAg and sustained suppression of HBV DNA for at least 24 weeks after stopping all treatment.
- ALT normalization: Return of liver enzyme levels to normal range, indicating reduced liver inflammation.
Safety and Side Effects
As ELEBSIRAN is still in clinical trials, its full safety profile is not yet established. The ongoing studies are closely monitoring for:
- Treatment-emergent adverse events (TEAEs)
- Serious adverse events (SAEs)
- Changes in laboratory values, including liver function tests
- Immune-related effects, such as the development of anti-drug antibodies
Patients participating in clinical trials are closely monitored for any potential side effects or safety concerns.
Conclusion
ELEBSIRAN represents a promising new approach in the treatment of chronic hepatitis B and D infections. By targeting viral genes and potentially reducing viral proteins, it may offer a novel way to suppress these persistent viral infections. However, as the drug is still in clinical trials, more research is needed to fully understand its efficacy, safety, and long-term benefits for patients with chronic HBV and HDV infections.